eview olecular properties of human IgG subclasses and their implications or designing therapeutic monoclonal antibodies against infectious iseases

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of Immune Responses by the Neonatal Fc Receptor and Its Therapeutic Implications

  2015cited by this paper
• Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding

  2015cited by this paper
• Immunoglobulin G (IgG) Fab Glycosylation Analysis Using a New Mass Spectrometric High-throughput Profiling Method Reveals Pregnancy-associated Changes*

  2014cited by this paper
• Therapeutic antibody engineering by high efficiency cell screening

  2014cited by this paper
• Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo

  2014cited by this paper
• FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions.

  2014cited by this paper
• Polyclonal and monoclonal antibodies in clinic.

  2014cited by this paper
• Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

  2014cited by this paper
• Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms

  2014cited by this paper
• Type I and type II Fc receptors regulate innate and adaptive immunity

  2014cited by this paper
• Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.

  2014cited by this paper
• Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.

  2014cited by this paper
• A pilot study showing differences in glycosylation patterns of IgG subclasses induced by pneumococcal, meningococcal, and two types of influenza vaccines

  2014cited by this paper
• Isotype Switching Increases Efficacy of Antibody Protection against Staphylococcal Enterotoxin B-Induced Lethal Shock and Staphylococcus aureus Sepsis in Mice

  2014cited by this paper
• IgG Subclasses and Allotypes: From Structure to Effector Functions

  2014cited by this paper
• On the Perplexingly Low Rate of Transport of IgG2 across the Human Placenta

  2014cited by this paper
• An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.

  2014cited by this paper
• Engineered Fc based antibody domains and fragments as novel scaffolds.

  2014cited by this paper
• Immunoglobulin G

  2014cited by this paper
• Interactions Between the Complement System and Fcγ Receptors

  2014cited by this paper
• Engineered Protease-resistant Antibodies with Selectable Cell-killing Functions*

  2013cited by this paper
• Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity.

  2013cited by this paper
• IgG Subclass and Heavy Chain Domains Contribute to Binding and Protection by mAbs to the Poly γ-D-glutamic Acid Capsular Antigen of Bacillus anthracis

  2013cited by this paper
• Chapter 10 - Antibody glycosylation

  2013cited by this paper
• Asymmetrical Fc Engineering Greatly Enhances Antibody-dependent Cellular Cytotoxicity (ADCC) Effector Function and Stability of the Modified Antibodies*

  2013cited by this paper
• Human IgG Subclasses against Enterovirus Type 71: Neutralization versus Antibody Dependent Enhancement of Infection

  2013cited by this paper
• The forgotten tale of immunoglobulin allotypes in cancer risk and treatment

  2013cited by this paper
• Therapeutic antibodies and infectious diseases, Tours, France, November 20−22, 2012

  2013cited by this paper
• Association of HCMV specific IgG subclass antibody levels with gender and age.

  2013cited by this paper
• Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

  2013cited by this paper
• Therapeutic antibodies as a treatment option for dengue fever

  2013cited by this paper
• Passive immunization for the public health control of communicable diseases: Current status in four high-income countries and where to next

  2013influential reference
• Adverse effects of human immunoglobulin therapy.

  2013influential reference
• Anti-bacterial monoclonal antibodies: back to the future?

  2012cited by this paper
• Isotype and glycoform selection for antibody therapeutics.

  2012cited by this paper
• Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

  2012cited by this paper
• Disulfide bond structures of IgG molecules

  2012cited by this paper
• Properties of mouse and human IgG receptors and their contribution to disease models.

  2012cited by this paper
• Human Gm, Km, and Am allotypes and their molecular characterization: a remarkable demonstration of polymorphism.

  2012cited by this paper
• Role of passive immunotherapies in managing infectious outbreaks.

  2012cited by this paper
• A conserved host and pathogen recognition site on immunoglobulins: structural and functional aspects.

  2012cited by this paper
• Passive immunization: the forgotten arm of immunologically based strategies for disease containment.

  2011cited by this paper
• Changes in Antigen-specific IgG1 Fc N-glycosylation Upon Influenza and Tetanus Vaccination

  2011cited by this paper
• Structural Basis for FcγRIIa Recognition of Human IgG and Formation of Inflammatory Signaling Complexes

  2011cited by this paper
• Immunoglobulin G (IgG) subclass deficiency in Thai children.

  2011cited by this paper
• Antibodies for biodefense

  2011cited by this paper
• Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose

  2011cited by this paper
• Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential

  2011cited by this paper
• Introduction to current and future protein therapeutics: a protein engineering perspective.

  2011cited by this paper
• Combined effects of Gm or Km immunoglobulin allotypes and age on antibody responses to Plasmodium falciparum VarO rosetting variant in Benin.

  2011cited by this paper
• Monoclonal Antibody Therapies against Anthrax

  2011cited by this paper
• Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia.

  2010cited by this paper
• Evaluation of Fab and F(ab′)2 Fragments and Isotype Variants of a Recombinant Human Monoclonal Antibody against Shiga Toxin 2

  2010cited by this paper
• A requirement for FcγR in antibody-mediated bacterial toxin neutralization

  2010cited by this paper
• Immunoglobulin GM 3 23 5,13,14 phenotype is strongly associated with IgG1 antibody responses to Plasmodium vivax vaccine candidate antigens PvMSP1-19 and PvAMA-1

  2010cited by this paper
• Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study

  2010cited by this paper
• Gram-Negative Bacteria

  2010cited by this paper
• Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review.

  2010cited by this paper
• Longitudinal analysis of serological responses of adults to Helicobacter pylori antigens.

  2010cited by this paper
• IgG2m4, an engineered antibody isotype with reduced Fc function

  2009cited by this paper
• IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab

  2009cited by this paper
• Selection and Characterization of Murine Monoclonal Antibodies to Staphylococcus aureus Iron-Regulated Surface Determinant B with Functional Activity In Vitro and In Vivo

  2009cited by this paper
• Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

  2009cited by this paper
• Inhibition of Erythrocyte Invasion and Plasmodium falciparum Merozoite Surface Protein 1 Processing by Human Immunoglobulin G1 (IgG1) and IgG3 Antibodies

  2009cited by this paper
• Immunoglobulin G Subclass-Specific Responses against Plasmodium falciparum Merozoite Antigens Are Associated with Control of Parasitemia and Protection from Symptomatic Illness

  2009cited by this paper
• Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn.

  2009cited by this paper
• Molecular Engineering III: Fc Engineering

  2008cited by this paper
• Analysis of immunoglobulin glycosylation by LC‐ESI‐MS of glycopeptides and oligosaccharides

  2008cited by this paper
• Immunoglobulin allotypes influence IgG antibody responses to hepatitis C virus envelope proteins E1 and E2.

  2008cited by this paper
• Monoclonal antibodies for prophylaxis and therapy of infectious diseases.

  2007cited by this paper
• The Neutralization Properties of a HIV-Specific Antibody Are Markedly Altered by Glycosylation Events Outside the Antigen-Binding Domain1

  2007influential reference
• Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.

  2007cited by this paper
• Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

  2007cited by this paper
• Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum

  2007cited by this paper
• Fc receptor but not complement binding is important in antibody protection against HIV

  2007cited by this paper
• Characterization of the Opsonic and Protective Activity against Staphylococcus aureus of Fully Human Monoclonal Antibodies Specific for the Bacterial Surface Polysaccharide Poly-N-Acetylglucosamine

  2006cited by this paper
• Why I Agreed to Do This

  2006cited by this paper
• Engineered antibody Fc variants with enhanced effector function.

  2006cited by this paper
• Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

  2006cited by this paper
• Anti-infective monoclonal antibodies: perils and promise of development

  2006cited by this paper
• Isolated IgG3 deficiency in children: to treat or not to treat? Case presentation and review of the literature

  2006cited by this paper
• Potent antibody therapeutics by design

  2006influential reference
• A mutant human IgG molecule with only one C1q binding site can activate complement and induce lysis of target cells

  2006cited by this paper
• Heterogeneity of IgG Glycosylation in Adult Periodontal Disease

  2005cited by this paper
• Of Mice and Not Men: Differences between Mouse and Human Immunology

  2004cited by this paper
• Structure and activation of the C1 complex of complement: unraveling the puzzle.

  2004cited by this paper
• Passive antibody therapy for infectious diseases

  2004cited by this paper
• Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies.

  2003cited by this paper
• The Crystal Structure of the Globular Head of Complement Protein C1q Provides a Basis for Its Versatile Recognition Properties*

  2003cited by this paper
• Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity.

  2003cited by this paper
• Expression and Functional Activity of Isotype and Subclass Switched Human Monoclonal Antibody Reactive with the Base of the V3 Loop of HIV-1 gp120

  2003influential reference
• Binding and Neutralization Activity of Human IgG1 and IgG3 from Serum of HIV-Infected Individuals

  2003cited by this paper
• Immunoglobulin G Monoclonal Antibodies to Cryptococcus neoformans Protect Mice Deficient in Complement Component C3

  2002cited by this paper
• Crystal structures of human antibodies: a detailed and unfinished tapestry of immunoglobulin gene products

  2002cited by this paper
• Immunoglobulin G subclass deficiency: Fact or fancy?

  2002cited by this paper
• Immunoglobulin G3 from Polyclonal Human Immunodeficiency Virus (HIV) Immune Globulin Is More Potent than Other Subclasses in Neutralizing HIV Type 1

  2001cited by this paper
• Engineered Antibodies with Increased Activity to Recruit Complement

  2001cited by this paper
• Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding.

  2001cited by this paper
• Early immune responses accompanying human asymptomatic Ebola infections

  2001cited by this paper
• The Structure of a Human Type III Fcγ Receptor in Complex with Fc*

  2001cited by this paper

• No citing papers are available for this paper.